Trademark: 79309216
Word
MEDIGENE IMMUNOTHERAPIES
Status Date
Tuesday, December 27, 2022
Registration Number
6932587
Registration Date
Tuesday, December 27, 2022
Filing Date
Tuesday, February 23, 2021
Published for Opposition
Tuesday, October 11, 2022
5 Medicines for humans and animals, vaccines, serums for medical purposes, and diagnostic preparations for medical purposes for treating cancer, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits for principally comprised of diagnostic preparations for medical purposes that contains at least one of soluble t-cell receptors, and genetically modified cells for determining the type and existence of a tumour in a patient, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; proteins and cells, namely, immune cells carrying a target specific effector protein, protein conjugates, peptides, enzymes and enzyme preparations, in particular antibodies and t-cell proteins, all for medical purposes; t-cells, dendritic cells other immune system cells, and viruses, all for medical purposes;plant extracts for medical purposes; medicines, vaccines, adjuvants, serums all for immunotherapy and the treatment of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits and diagnostic agents comprised of medical diagnostic preparations that contain at least one of soluble t-cell receptors and genetically modified cells for the diagnosis of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods
44 Medical analysis and medical consulting in connection with the treatment of individuals, in particular in the field of precancerous cells, benign and malignant tumours, autoimmune diseases and immunotherapy
42 Custom molecular biology and biotechnology laboratory services, in particular custom research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, genetic engineering and biotechnological methods to the specifications of others, and in the field of screening for pharmaceutically active components; development of custom test procedures and custom test kits in the field of biotechnology and medicine to the specification of others
MEDI GENE IMMUNOTHERAPY'S
"IMMUNOTHERAPIES"
May 1, 2023
Final Decision Transaction Processed By Ib
Apr 6, 2023
Final Disposition Notice Sent To Ib
Apr 6, 2023
Final Disposition Processed
Mar 27, 2023
Final Disposition Notice Created, To Be Sent To Ib
Dec 27, 2022
Notice Of Registration Confirmation Emailed
Dec 27, 2022
Registered-Principal Register
Oct 17, 2022
Notification Of Possible Opposition - Processed By Ib
Oct 11, 2022
Official Gazette Publication Confirmation E-Mailed
Oct 11, 2022
Published For Opposition
Oct 10, 2022
Notification Processed By Ib
Sep 28, 2022
Notification Of Possible Opposition Sent To Ib
Sep 28, 2022
Notification Of Possible Opposition Created, To Be Sent To Ib
Sep 21, 2022
Notification Of Possible Opposition Sent To Ib
Sep 21, 2022
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Sep 21, 2022
Notification Of Notice Of Publication E-Mailed
Sep 7, 2022
Approved For Pub - Principal Register
Sep 7, 2022
Examiner's Amendment Entered
Sep 7, 2022
Notification Of Examiners Amendment E-Mailed
Sep 7, 2022
Examiners Amendment E-Mailed
Sep 7, 2022
Examiners Amendment -Written
Apr 14, 2022
Notification Of Final Refusal Emailed
Apr 14, 2022
Final Refusal E-Mailed
Apr 14, 2022
Final Refusal Written
Mar 30, 2022
Teas/Email Correspondence Entered
Mar 30, 2022
Correspondence Received In Law Office
Mar 30, 2022
Teas Response To Office Action Received
Oct 30, 2021
Refusal Processed By Ib
Oct 1, 2021
Non-Final Action Mailed - Refusal Sent To Ib
Oct 1, 2021
Refusal Processed By Mpu
Sep 27, 2021
Non-Final Action (Ib Refusal) Prepared For Review
Sep 26, 2021
Non-Final Action Written
Sep 17, 2021
Assigned To Examiner
Apr 27, 2021
Application Filing Receipt Mailed
Apr 23, 2021
New Application Office Supplied Data Entered
Apr 22, 2021
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
